Key Takeaways MindMed is enrolling two phase III GAD studies with top-line data due in 2026. MNMD's phase III Emerge study in MDD enrolled faster, with top-line data now expected in mid-2026.MindMed shares rose 101.2% in six months. A $258.9M financing strengthens its balance sheet.Mind Medicine (MindMed) (MNMD) is developing its lead pipeline candidate MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate, for the treatment of generalized anxiety disorde ...